Evidence for Efficacy of Drugs Affecting Bone Metabolism in Preventing Hip Fracture

Overview

Journal BMJ

Specialty General Medicine

Date 1992 Nov 7

PMID 1463947

Citations 50

Authors

J A Kanis

O Johnell

B Gullberg

E Allander

G DILSEN

C Gennari

A A Lopes Vaz

G P Lyritis

G Mazzuoli

L MIRAVET

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the effects of taking drugs affecting bone metabolism on the risk of hip fracture in women aged over 50 years.

Design: Retrospective, population based, case-control study by questionnaire.

Setting: 14 centres in six countries in southern Europe.

Subjects: 2086 women with hip fracture and 3532 control women matched for age.

Main Outcome Measures: Number of drugs affecting bone metabolism taken and length taken for.

Results: Women taking drugs affecting bone metabolism had a significantly decreased risk of hip fracture. After adjustment for differences in other risk factors, the relative risk of hip fractures was 0.55 (95% confidence interval 0.31 to 0.85) in women taking oestrogens, 0.75 (0.60 to 0.94) in those taking calcium, and 0.69 (0.51 to 0.92) in those taking calcitonin. The fall in risk was not significant for anabolic steroids (0.6 (0.29 to 1.22)). Neither vitamin D nor fluorides were associated with a significant decrease in the risk of hip fracture. The effect on hip fracture risk increased significantly with increasing duration of exposure (risk ratio 0.8 (0.61 to 1.05) for less than median exposure v 0.66 (0.5 to 0.88) for greater than median exposure). Drugs were equally effective in older and younger women, with the exception of oestrogen.

Conclusions: Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture. Short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fracture.

Citing Articles

Calcitonin: A useful old friend.

Srinivasan A, Wong F, Karponis D J Musculoskelet Neuronal Interact. 2020; 20(4):600-609.

PMID: 33265089 PMC: 7716677.

Bio-structural monitoring of bone mineral alterations through electromechanical impedance measurements of a Piezo-device joined to a tooth.

Tinoco H, Cardona C, Marin-Berrio M, Garcia-Grisales J, Gomez J, Roldan S Biomed Eng Lett. 2020; 10(4):603-617.

PMID: 33194251 PMC: 7655898. DOI: 10.1007/s13534-020-00170-9.

Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations.

Xie J, Guo J, Kanwal Z, Wu M, Lv X, Ibrahim N Int J Endocrinol. 2020; 2020:3236828.

PMID: 32963524 PMC: 7501564. DOI: 10.1155/2020/3236828.

European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster J Osteoporos Int. 2012; 24(1):23-57.

PMID: 23079689 PMC: 3587294. DOI: 10.1007/s00198-012-2074-y.

Oral calcitonin.

Maricic M Curr Osteoporos Rep. 2012; 10(1):80-5.

PMID: 22281725 DOI: 10.1007/s11914-011-0084-x.

References

Browner W, Seeley D, Vogt T, Cummings S . Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet. 1991; 338(8763):355-8. DOI: 10.1016/0140-6736(91)90489-c. View

Weiss N, Ure C, Ballard J, Williams A, Daling J . Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980; 303(21):1195-8. DOI: 10.1056/NEJM198011203032102. View

Dawson-Hughes B, Dallal G, Krall E, Harris S, Sokoll L, Falconer G . Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Ann Intern Med. 1991; 115(7):505-12. DOI: 10.7326/0003-4819-115-7-505. View

Law M, Wald N, Meade T . Strategies for prevention of osteoporosis and hip fracture. BMJ. 1991; 303(6800):453-9. PMC: 1670562. DOI: 10.1136/bmj.303.6800.453. View

Dequeker J, Tobing L, Rutten V, Geusens P . Relative risk factors for osteoporotic fracture: a pilot study of the MEDOS questionnaire. Clin Rheumatol. 1991; 10(1):49-53. DOI: 10.1007/BF02208033. View

Storm T, Thamsborg G, Steiniche T, Genant H, Sorensen O . Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990; 322(18):1265-71. DOI: 10.1056/NEJM199005033221803. View

Watts N, Harris S, Genant H, Wasnich R, Miller P, Jackson R . Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323(2):73-9. DOI: 10.1056/NEJM199007123230201. View

Naessen T, Persson I, Adami H, Bergstrom R, Bergkvist L . Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med. 1990; 113(2):95-103. DOI: 10.7326/0003-4819-113-2-95. View

Riggs B, Hodgson S, OFallon W, Chao E, Wahner H, Muhs J . Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322(12):802-9. DOI: 10.1056/NEJM199003223221203. View

10.

Kanis J, PASSMORE R . Calcium supplementation of the diet--I. BMJ. 1989; 298(6667):137-40. PMC: 1835487. DOI: 10.1136/bmj.298.6667.137. View

11.

Ott S, Chesnut 3rd C . Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989; 110(4):267-74. DOI: 10.7326/0003-4819-110-4-267. View

12.

Ettinger B, Genant H, Cann C . Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985; 102(3):319-24. DOI: 10.7326/0003-4819-102-3-319. View

13.

Cooper C, Barker D, Wickham C . Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. BMJ. 1988; 297(6661):1443-6. PMC: 1835123. DOI: 10.1136/bmj.297.6661.1443. View

14.

Kanis J . Treatment of osteoporotic fracture. Lancet. 1984; 1(8367):27-33. DOI: 10.1016/s0140-6736(84)90191-0. View

15.

Chesnut 3rd C, Ivey J, Gruber H, Matthews M, Nelp W, Sisom K . Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism. 1983; 32(6):571-80. DOI: 10.1016/0026-0495(83)90027-6. View

16.

Kanis J, Geusens P, Christiansen C . Guidelines for clinical trials in osteoporosis. A position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1991; 1(3):182-8. DOI: 10.1007/BF01625451. View